BioSpace News Archive

A quick overview of life science companies scooping up some summer spending money this week.

Biogen reportedly withdrew a paper it had submitted to the medical journal JAMA after the publication requested edits before publication. It’s standard for a technical journal to request edits, but it is the nature of the edits—and in this case, the nature of the study— that raises questions.

Three companies, including two biotech companies and one drug discovery company, announced yesterday the successful closing of Series A financing, with IMIDomics taking the lead.

“For the first time in history, medicine has become information.” That’s the groundbreaking connection AI-driven RNA therapeutics has given us, according to Deep Genomics Founder and CEO Brendan Frey.

The medical beds market was valued at US$ 3,580.52 million in 2018 and it is projected to reach US$ 5,710.7 million in 2027; it is expected to grow at a CAGR of 5.4% from 2019 to 2027.

PolarityTE, Inc. announced final data from a multi-center randomized controlled trial evaluating treatment of Diabetic Foot Ulcers with its investigational product SkinTE® plus standard of care vs SOC alone.

Apic Bio, Inc., an innovative gene therapy company developing novel treatment options for patients with rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to APB-102, the Company’s lead gene therapy candidate designed to treat SOD1 amyotrophic lateral sclerosis (ALS).

NewAmsterdam Pharma (NAP), a clinical-stage company focused on the research and development of transformative therapies for cardiometabolic diseases, today announced statistically significant and clinically robust LDL-c lowering results in its recently completed Phase 2 clinical study evaluating oral obicetrapib, an investigational novel selective cholesteryl ester transfer protein (CETP) inhibitor.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the company will initiate a Phase 3 development program for the new once-daily investigational triple combination of VX-121/tezacaftor/VX-561 (deutivacaftor) in the second half of 2021.

National Resilience, Inc. (Resilience) and bluebird bio, Inc. (NASDAQ: BLUE), today announced a strategic alliance aimed to accelerate the early research, development and delivery of cell therapies.